Skip to main content
Signal8

Aguirre Jarrad Mattieu

SEC insider (Form 3/4/5 filer). CIK 0002150331. Chief Medical Officer at Lyell Immunopharma, Inc. (LYEL). 2 reported Form 4/5 transactions since Sep 2024; latest on Oct 12, 2026. Located in SOUTH SAN FRANCISCO, CA.

Companies Aguirre Jarrad Mattieu has filed insider reports for

  • Lyell Immunopharma, Inc. (LYEL): Officer, Chief Medical Officer
Aguirre Jarrad Mattieu profile photo

Aguirre Jarrad Mattieu

CIK: 0002150331

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (50.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Lyell Immunopharma, Inc. logo
LYEL

Lyell Immunopharma, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (2 total)

  • Lyell Immunopharma, Inc. logo
    LYEL

    Lyell Immunopharma, Inc.

    Oct 12, 2026
    Sale
    Direct
    422 shares at avg. $8.63$4K
  • Lyell Immunopharma, Inc. logo
    LYEL

    Lyell Immunopharma, Inc.

    Sep 10, 2026
    Award

    Option (right to buy)

    Direct
    47.5K shares-

1-2 of 2